The aberrant signaling by ERBB family members, driven by genetic mutations that abnormally activate tyrosine kinase, can propel tumor initiation, progression, and severity, concurrently undermining the antitumor immune response by modulating the tumor microenvironment’s immune profile (Kumagai et al., 2021). Here, EGFR is linked to neoplasm.